Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Xing-Yun Liao"'
Autor:
Ling-Chen Li, Xie-Wan Chen, Ling Fang, Chun-Li Jian, Yong-Xin Yu, Xing-Yun Liao, Jian-Guo Sun
Publikováno v:
Canadian Respiratory Journal, Vol 2023 (2023)
Background. Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This stud
Externí odkaz:
https://doaj.org/article/cefbf99075a74e289026c7edcddeb7a7
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
Abstract Background Among non-small cell lung cancer (NSCLC) patients with acquired T790 M mutation resistance to first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), 71% are likely to benefit from osimertinib. Ther
Externí odkaz:
https://doaj.org/article/36e6aedfb67a4d2b84da9b1441257ad7
Publikováno v:
Oncology Letters
A series of antibodies against vascular endothelial growth factor (VEGF) have been developed for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC) in recent years. However, tumors frequently demonstrate resistance
Autor:
Xu Chen, Kai Niu, Tao Li, Jianguo Sun, Zhengtang Chen, De-zhi Li, Yan-Mei Xu, Yuzhong Duan, Xing-Yun Liao, Rongxia Liao, Luping Zhang
Publikováno v:
Tumour Biology
Background Radioresistance of thoracic radiotherapy is a major bottleneck in the treatment of non-small cell lung cancer (NSCLC). Until now, there have been no effective biomarkers to predict the radiosensitivity. Purposes Based on miRNA profile scre
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
Background Among non-small cell lung cancer (NSCLC) patients with acquired T790 M mutation resistance to first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), 71% are likely to benefit from osimertinib. There have be
Autor:
Bo Zhu, Yuzhong Duan, Zihan Xu, Qiao Yang, Yanmei Wang, Linpeng Zheng, Jianguo Sun, Guangkuo Zhu, Xing-Yun Liao, Xiewan Chen
Publikováno v:
The Oncologist
Lessons Learned This single-arm, phase II study shows that concurrent EGFR-tyrosine kinase inhibitor plus thoracic radiotherapy as the first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations provides long-term con
Autor:
Yu-Zhong Duan, Yan-Mei Xu, Luping Zhang, Xing-Yun Liao, Lv-Jun Yan, Xinxin Wang, Gui-Fang Yan, Jianguo Sun
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 14:4255-4259
Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. T
Autor:
Jun Qiu, Luping Zhang, Xing-Yun Liao, Zhong-Ming Feng, Xiewan Chen, Yan Li, Xu Chen, Jianguo Sun, Rongxia Liao, Zhengtang Chen
Publikováno v:
BMC Cancer
Background Breast cancer stem cells (BCSCs) have been reported as the origin of breast cancer and the radical cause of drug resistance, relapse and metastasis in breast cancer. BCSCs could be derived from mutated mammary epithelial stem cells (MaSCs)
Publikováno v:
BioMed Research International
BioMed Research International, Vol 2015 (2015)
BioMed Research International, Vol 2015 (2015)
Radiotherapy (RT) is a key therapeutic strategy for lung cancer, the most common cause of cancer-related deaths worldwide, but radioresistance often occurs and leads to failure of RT. It is therefore important to clarify the mechanism underlying radi
Publikováno v:
Oncology Letters; Jul2017, Vol. 14 Issue 1, p615-622, 8p, 2 Charts, 4 Graphs